

Special Issue

Cardiac Electrophysiology and Pharmacology 2024

Message from the Guest Editors

Classical antiarrhythmic therapy includes the application of several Na⁺-, K⁺- and Ca²⁺-channel blockers. However, pharmacological interventions are still hampered because the compounds often exert a lack of selectivity and/or proarrhythmic side-effects. A further important aspect of the unsatisfactory pharmacological treatments is the lack of sufficient knowledge of the underlying mechanisms underlying several diseases. A better understanding of cardiac electrophysiology, could improve the effectiveness of pharmacological treatments and may decrease proarrhythmic risk. Pharmacological modulation of the electrical properties of the heart is also critically important for improvements in ideal pharmacological strategies. Novel techniques may help explore the pharmacological and physiological properties of ion channels that are difficult to measure using conventional techniques. The engineering and comprehensive analysis of novel, more specific pharmacological compounds are also necessary to specifically characterize an ion channel function and provide novel strategies for pharmacological interventions.

Guest Editors

Dr. Noémi Tóth

1. Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, Charleston, SC, USA
2. HU-REN-SZTE Research Group for Cardiovascular Pharmacology, 6720 Szeged, Hungary

Dr. Norbert Nagy

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6721 Szeged, Hungary

Deadline for manuscript submissions

closed (25 June 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/192506

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)